At the 63rd ERA Congress, researchers unveiled findings that reframe how doctors think about treating one of the world's most pressing health challenges: a once-weekly injection called semaglutide not only slows kidney disease progression in people with type 2 diabetes, it also gives them something equally precious—eight additional days each year of full, healthy functioning. The FLOW trial, which followed 3,533 people over a median of 3.4 years, demonstrates that the benefits of semaglutide extend far beyond what traditional medical metrics capture.
For the 850 million people globally living with chronic kidney disease, the weight of the condition is personal and relentless. Symptoms, medication burden, and declining physical capacity erode daily life in ways that clinical trial endpoints alone cannot measure. Patients speak, consistently, about wanting not just to live longer but to live better. The FLOW trial took this patient perspective seriously.
Researchers divided 3,533 participants into two groups: 1,767 received semaglutide and 1,766 received placebo. Both groups completed the EQ-5D-5L questionnaire at baseline and yearly thereafter—a detailed patient-reported measure asking about mobility, self-care, ability to do usual activities, pain and discomfort, anxiety and depression, and overall health perception. After two years, the results told a clear story. Health utility scores (which range from 0 for death to 1 for perfect health) remained stable in those taking semaglutide but declined in those on placebo. That +0.021 treatment difference may sound small until you translate it: approximately eight additional days per year spent in full health.
The improvements touched multiple dimensions of life. Self-rated general health improved with semaglutide while worsening with placebo—a difference of +2.15 points. Four of the five specific life domains showed significant gains: mobility, self-care, usual activities, and pain or discomfort all improved meaningfully compared with placebo. Only anxiety and depression showed no significant difference between the two groups.
These quality-of-life findings complement what the FLOW trial already revealed. Earlier analysis showed semaglutide reduced the risk of major kidney disease events by 24% and all-cause mortality by 20% compared with placebo. What surprised researchers, including lead author Professor Johannes Mann, was that such substantial improvements in how patients felt and functioned were possible despite gastrointestinal side effects being common with GLP-1 receptor agonists like semaglutide.
"We were uncertain about quality-of-life outcomes because gastrointestinal side effects are common with GLP-1 receptor agonists," Mann reflected. "Our findings, however, confirm that the benefits of semaglutide in chronic kidney disease extend beyond traditional clinical endpoints to subjective outcomes that matter directly to patients."
The benefits held steady across different patient groups—regardless of age, weight, kidney function level, or previous cardiovascular events. This consistency suggests the findings could apply broadly to the millions who need these treatments.
The implications reshape clinical conversations. When doctors discuss treatment options with patients carrying both type 2 diabetes and chronic kidney disease, quality of life now has evidence behind it as a legitimate and achievable goal. For patients, it means the chance not just to extend life but to live the years they have with greater freedom, less pain, and better capacity to do the things that matter.